Back to top

Image: Bigstock

Victory Capital August AUM Improves on Higher Equity Assets

Read MoreHide Full Article

Victory Capital Holdings (VCTR - Free Report) has announced assets under management (AUM) by its subsidiaries of $136.8 billion for August 2020. It reflects a 3.2% rise from $132.5 billion recorded as of Jul 31, 2020.

At August-end, the company’s U.S. Mid Cap Equity AUM grew 2.8% from July-end to $23.6 billion. U.S. Small Cap Equity and Global/Non-U.S. Equity AUM of $15.2 billion and $12.2 billion increased 7.8% and 4.3%, respectively. Further, U.S. Large Cap Equity AUM rose 5.1% from July to $13.8 billion.

Victory Capital recorded $31.9 billion in Solutions, up 4.7% from $29.3 billion reported in July. Other assets increased 9.6% to $229 million on a sequential basis. Also, Fixed Income assets were $36.1 billion, down slightly from the prior month.

Sound positioning of Victory Capital’s integrated multi-boutique business model in a rapidly evolving industry, and effectiveness of the distribution platform might keep supporting its performance.

Shares of the company have gained 1% over the past year against the industry’s 3.5% decline.

Currently, Victory Capital carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Asset Managers

AllianceBernstein Holding L.P. (AB - Free Report) announced AUM for August 2020. The company’s preliminary month-end AUM of $643 billion increased 3.2% from the prior month. Market appreciation and total firm-wide net inflows primarily drove this rise.

Franklin Resources (BEN - Free Report) announced preliminary AUM by its subsidiaries of $1.44 trillion for August 2020. Results display a 0.7% increase from the $1.43 trillion recorded as of Jul 31, 2020.

Invesco (IVZ - Free Report) announced preliminary August-end AUM of $1,245.8 billion, which represents a 4.2% increase from the previous month.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>